Video: Promising Horizons In Non-Small Cell Lung Cancer
—"The tide is turning," says Laurie Matt-Amaral, MD, of Cleveland Clinic. Recent advances in the field of NSCLC are changing the landscape of the disease. (1:10)
Published:
This retrospective analysis found that overall survival in NSCLC was significantly worse among patients with T3 tumors characterized by parietal pleura infiltration or chest wall infiltration than those characterized by size or the presence of a separate tumor nodule in the same lobe.
Is there something that we can control? That's the question at heart when analyzing the tumor microenvironment, explains Laurie Matt-Amaral, MD, of Cleveland Clinic. In this video, she breaks down the components of the tumor microenvironment and how it's used to guide treatment. (2:58)
Laurie Matt-Amaral, MD, of Cleveland Clinic, discusses HER3, cMET, and more, and where she sees the field heading in the future. (1:33)
A study found that patients with distant recurrent metastatic non-small cell lung cancer had significantly better overall survival than those with de novo stage IV disease. These results may help inform clinical trial designs to ensure balanced baseline characteristics.
A lung cancer screening test examining small noncoding RNAs has demonstrated the ability to identify lung cancer using whole blood collected in the clinical setting, making it a potential alternative to low-dose computed tomography.
Neoadjuvant chemoimmunotherapy may be limited in use and accessibility. These researchers analyzed the potential barriers, including socioeconomic status, geographical location, and insurance status.